Zai Lab Appoints Lonnie Moulder to Board of Directors - TC Read more about Zai Lab Appoints Lonnie Moulder to Board of Directors - TC
ZL-2306 (Niraparib) receives the second funding support from National “Significant New Drugs Development Project” - TC Read more about ZL-2306 (Niraparib) receives the second funding support from National “Significant New Drugs Development Project” - TC
Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer - TC Read more about Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer - TC
ZL-2401 (Omadacycline) received funding support from National “Significant New Drugs Development Project” - TC Read more about ZL-2401 (Omadacycline) received funding support from National “Significant New Drugs Development Project” - TC
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer - TC Read more about Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer - TC
Zai Lab Announces Upcoming Presentation at 38th Annual J.P. Morgan Healthcare Conference - TC Read more about Zai Lab Announces Upcoming Presentation at 38th Annual J.P. Morgan Healthcare Conference - TC
Zai Lab Announces the Appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board - TC Read more about Zai Lab Announces the Appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board - TC
Zai Lab Awarded Commercial Achievement of the Year - TC Read more about Zai Lab Awarded Commercial Achievement of the Year - TC
Zai Lab Announces Upcoming Presentations at November Conferences TC Read more about Zai Lab Announces Upcoming Presentations at November Conferences TC
Zai Lab Partner, MacroGenics, Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer - TC Read more about Zai Lab Partner, MacroGenics, Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer - TC